Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumor”

140 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 140 results

Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Not applicableLooking for participantsNCT07319416
What this trial is testing

DCEUS to Assess Treatment Response to PRRT in GEP-NET

Who this might be right for
NETRadionucleide TherapyContrast Enhanced Ultrasound
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Testing effectiveness (Phase 2)Study completedNCT04296149
What this trial is testing

Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe

Who this might be right for
Neuroendocrine Tumors
European Institute of Oncology 5
Large-scale testing (Phase 3)Study completedNCT02608203
What this trial is testing

[68 Ga]-DOTANOC PET/CT in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Assistance Publique Hopitaux De Marseille 18
Testing effectiveness (Phase 2)WithdrawnNCT03901378
What this trial is testing

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site
Ochsner Health System
Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Not applicableLooking for participantsNCT05196087
What this trial is testing

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Who this might be right for
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto 500
Testing effectiveness (Phase 2)UnknownNCT05709171
What this trial is testing

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Who this might be right for
GEP-NETNeuroendocrine TumorsNeuroendocrine Carcinoma+1 more
Rigshospitalet, Denmark 200
Early research (Phase 1)Ended earlyNCT05364944
What this trial is testing

Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
AcromegalyGEP-NET
Debiopharm International SA 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706
What this trial is testing

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Who this might be right for
Peritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more
Hospices Civils de Lyon 27
Early research (Phase 1)Active Not RecruitingNCT03833700
What this trial is testing

E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Who this might be right for
Solid NeoplasmsColorectal NeoplasmsGastrointestinal Tumors
Eisai Co., Ltd. 70
Early research (Phase 1)Study completedNCT05262556
What this trial is testing

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more
Amr Mohamed MD 15
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Not applicableUnknownNCT06402695
What this trial is testing

Observational Study on GEP-and Pulm-NET Treated at FPG

Who this might be right for
Neuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 650
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Next Page
116